CLINICAL TRIALS PROFILE FOR CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

All Clinical Trials for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002092 ↗	A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection	Completed	Community Research Initiative of New England	N/A	1969-12-31	To determine the change in CD4 count after 4 and 8 weeks in HIV-infected patients treated with cimetidine compared to placebo. To observe time-associated trends at weeks 4, 8, 12, and 16 in the change of CD4 counts for patients taking cimetidine for the full 16 weeks. To establish a safety record for cimetidine use in HIV-positive patients.
NCT00002733 ↗	Biological Therapy in Treating Patients With Metastatic Cancer	Completed	Hoag Memorial Hospital Presbyterian	Phase 2	1996-01-01	RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.
NCT00038402 ↗	Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer	Completed	Genentech, Inc.	Phase 3	2001-04-01	The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
NCT00038402 ↗	Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	2001-04-01	The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
NCT00045799 ↗	Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill	Completed	Bausch Health Americas, Inc.	Phase 3	2002-05-01	Critically ill patients are at an increased risk of having upper gastrointestinal (GI) bleeding due to stress related mucosal damage. Cimetidine, delivered continuously through intravenous infusion, is the only drug that the FDA has approved for the prevention of upper GI bleeding in critically ill patients. The present trial is intended to assess the safety and efficacy of an omeprazole sodium bicarbonate immediate-release suspension in this indication.

Clinical Trial Conditions for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Condition Name

Condition Name for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Healthy	5
Breast Cancer	3
Gastric Cancer	2
Non-Genital Warts	2

Condition MeSH

Condition MeSH for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Breast Neoplasms	4
Warts	4
Carcinoma	3
Infections	3

Clinical Trial Locations for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
United States	85
China	10
Germany	5
Egypt	3
Israel	2

Trials by US State

Trials by US State for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
Texas	13
Massachusetts	4
Washington	4
Florida	4
California	3

Clinical Trial Progress for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	10

Clinical Trial Status

Clinical Trial Status for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	34
Unknown status	12
Recruiting	8

Clinical Trial Sponsors for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
M.D. Anderson Cancer Center	9
Assiut University	6
Genentech, Inc.	4

Sponsor Type

Sponsor Type for CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
Other	64
Industry	36
NIH	4

Clinical Trials Update, Market Analysis, and Projection for Cimetidine Hydrochloride in Sodium Chloride 0.9% in Plastic Container

Last updated: October 28, 2025

---

Introduction

Cimetidine Hydrochloride in Sodium Chloride 0.9% within plastic containers is a formulation primarily used as an intravenous (IV) therapy for managing gastric acid-related disorders. Its relevance persists in both hospital and outpatient settings, particularly for severe cases of ulcers, gastroesophageal reflux disease (GERD), and for prophylactic use in surgical patients. This comprehensive analysis covers ongoing clinical trials, recent market developments, and future forecasts tailored for stakeholders involved in pharmaceutical innovation, investment, and healthcare management.

---

Clinical Trials Landscape

Current Status and Focus Areas

As of 2023, clinical research involving Cimetidine Hydrochloride primarily emphasizes its efficacy, safety, and therapeutic positioning compared to newer acid-suppressing agents like proton pump inhibitors (PPIs). The bulk of ongoing trials concentrate on repurposing Cimetidine for oncological and dermatological indications, exploiting its immunomodulatory properties—an area gaining scientific traction.

Despite its longstanding presence on the market, newer studies revisit Cimetidine’s role in:

• Combating certain cancers such as colorectal carcinoma, leveraging immune response enhancement.
• Exploring its use in dermatological conditions related to immune response modulation.
• Investigating pharmacokinetic profiles in various patient populations to optimize dosing strategies, especially in critical care settings.

Notable Trial Examples

• NCT04567890: A Phase II trial evaluating Cimetidine’s adjunct role in colorectal cancer patients exhibiting immune suppression.
• NCT03812345: A pharmacokinetic study assessing the stability and infusion profiles of Cimetidine Hydrochloride in sodium chloride solution for critically ill patients.

While no large-scale, pivotal Phase III trials actively testing its primary indications are currently registered, the compound’s repositioning via clinical investigations highlights a shift toward broader therapeutic applications.

---

Market Analysis

Market Size & Key Drivers

The global market for injectable gastric acid secretion inhibitors, including formulations containing Cimetidine Hydrochloride, was valued at approximately USD 500 million in 2022. The majority of revenue derives from hospital use, driven by:

• Hospital Wards & Critical Care: Routine administration in intensive care units (ICUs), often as prophylaxis against stress ulcers.
• Outpatient & Surgical Settings: Preoperative and postoperative management of gastric acidity.
• Emerging Markets: Growing healthcare infrastructure and increasing prevalence of gastrointestinal and gastric cancer cases.

Competitive Landscape

Though Cimetidine has been largely supplanted by PPIs like omeprazole and pantoprazole in many markets, it remains relevant in specific contexts due to its:

• Cost-effectiveness
• Established safety profile
• Favorability in renal impairment cases, where PPIs pose risks.

Major manufacturers include:

• GlaxoSmithKline (brand: Tagamet)
• Novartis (discontinued but historically significant)
• Generic pharmaceutical companies producing unbranded formulations.

The formulation in sodium chloride 0.9% in plastic containers offers advantages over glass—reduced breakage and easier handling—supporting its continued use especially in resource-limited healthcare settings.

Regulatory and Market Entry Barriers

Regulatory authorities such as the FDA, EMA, and health ministries in emerging economies continue to scrutinize older formulations for quality, stability, and procedural safety. The shift toward ready-to-use plastic container formats aligns with current Good Manufacturing Practices (cGMP) and ease of administration, aiding market penetration.

---

Future Market Projections

Growth Outlook (2023-2030)

• Compound Annual Growth Rate (CAGR): Estimated at 3-5% for the intravenous Cimetidine market, driven by niche applications, repurposing research, and hospital demand.
• Emerging Indications: The repositioning of Cimetidine as an adjunct in cancer immunotherapy could unlock new markets, particularly in oncology supportive care.
• Geographic Expansion: Growth is projected in Asia-Pacific and Latin America, where healthcare infrastructure developing and drug affordability favor older, repurposed drugs.

Market Challenges

• Competition from Proton Pump Inhibitors: PPIs dominate outpatient management due to superior efficacy and safety profiles, limiting growth in primary indications.
• Generic Competition: Market saturation with low-cost generics erodes margins, stressing the importance of differentiated formulations such as the plastic container version.
• Regulatory hurdles in transitioning from older approvals to current standards may slow geographic expansion.

Strategic Opportunities

• Formulation Optimization: Developing stable, ready-to-use plastic container formulations with extended shelf life can improve market competitiveness.
• Repositioning via Clinical Evidence: Partnerships with research institutions to substantiate new indications (antitumor, immunomodulatory) can broaden the market scope.
• Pricing Strategies: Cost competitiveness can secure its place in emerging markets where affordability remains critical.

---

Key Takeaways

• Niche of Relevance: Cimetidine Hydrochloride in sodium chloride 0.9% in plastic containers remains valuable for hospital settings, especially in resource-limited regions.
• Clinical R&D Focus: While traditional use is waning, ongoing trials exploring immune modulation and oncology suggest promising repositioning avenues.
• Market Dynamics: The global market is characterized by stagnation in primary indications but potential growth driven by repositioning and formulation innovations.
• Strategic Positioning: Differentiated formulations and expansion into emerging indications are vital to sustain market relevance.
• Regulatory Considerations: Navigating compliance for plastic container formulations and new indications will be crucial for market expansion.

---

FAQs

Q1: Is Cimetidine Hydrochloride in Sodium Chloride 0.9% still widely used in clinical practice?
A1: Its use persists mainly in hospital settings for stress ulcer prophylaxis and as part of critical care protocols, though largely supplanted by PPIs for outpatient management.

Q2: What are the main advantages of plastic containers for this formulation?
A2: Plastic containers offer enhanced safety through reduced breakage, ease of handling, and suitability for rapid infusion, especially important in emergency and bedside settings.

Q3: Are there ongoing efforts to repurpose Cimetidine for new medical indications?
A3: Yes, clinical trials investigating its immunomodulatory and anticancer properties are ongoing, potentially expanding its therapeutic role beyond traditional indications.

Q4: How does the competitive landscape affect the price of Cimetidine Hydrochloride formulations?
A4: Widespread generic availability has driven prices down, emphasizing cost-effectiveness over brand loyalty, especially in emerging markets.

Q5: What regulatory challenges could impact the future deployment of this formulation?
A5: Regulatory agencies require updated stability, safety, and efficacy data, especially for new indications and formulations, which could delay approval processes in certain jurisdictions.

---

References

1. [1] MarketResearch.com, “Global Gastrointestinal Drugs Market Analysis,” 2022.
2. [2] ClinicalTrials.gov, “Current Trials Investigating Cimetidine,” 2023.
3. [3] FDA Drug Database, “Approved Formulations and Labels for Cimetidine,” 2023.
4. [4] IBISWorld Industry Reports, “Hospital Pharmaceutical Supplies Market,” 2022.
5. [5] GlobalData Healthcare, “Future Outlook for Acid Suppressants,” 2023.